Bioventus Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon, everybody. My name is Jenny Rabinowitz. I cover US MedTech and Healthcare here at Goldman. And today, I'm thrilled to be joined by Bioventus.
To my left, we have Mark Singleton, CFO; and Dave Crawford, VP, Treasurer and IR. Starting off, it would be great to start with the company introduction. The markets you serve, your three key segments. What of the key products in all of them?
Great. Thank you for having us. Appreciate it. Bioventus is a $568 million revenue company as of 2025. Our guidance for 2026 is $605 million.
We participate in markets of $6 billion plus. So a lot of opportunity. We've had a lot of success over the last few years, accelerating our revenue, expanding our margins and generating significant amount of cash flow. We've actually taken our margins from early 2022 to 13% EBITDA to greater than 20% in 2025. And so we've increased them by 700 basis points.
At the same
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
